Palmaz Julio C
The University of Texas Health Science Center, San Antonio, Texas 78229, USA.
J Endovasc Ther. 2004 Dec;11 Suppl 2:II200-206. doi: 10.1177/15266028040110S617.
The first balloon-expandable coronary stent was approved "for the prevention of restenosis" in 1994, the same year that the Journal of Endovascular Therapy was inaugurated. Since then, the development of the stent has paralleled the evolution of endovascular intervention as a new specialty. Innovators have pushed to explore new and varied stent applications outside the coronary arteries. Carotid stenting, transjugular intrahepatic portocaval shunts, and covered stents are a few of these new applications that have now become commonplace. Dozens of stent designs and several new materials have been tested to solve the problem of in-stent restenosis, but it is the drug-eluting stent (DES) that has emerged as the most promising, at least in the coronary arteries. However, the benefits of DES technology are not likely to be effective in the more pervasive forms of in-stent restenosis, such as encountered in the femoropopliteal segment. In the future, technologies aimed at stimulating rather than inhibiting tissue response to an implant may be part of the next wave of developments, as we take aim against the poor and/or slow tissue incorporation that manifests as leaks and dislodgement. In the superficial femoral artery, for example, mechanical stresses that cause fractures and dislocations may be addressed by using a very flexible endovascular device with a tissue-friendly inner surface that promotes rapid stent endothelialization to counter the biological effects of motion and microtrauma. The rapidly developing fields of nanotechnology, microelectronics, and advanced materials technology will enable the surface engineer to design molecular-specific surfaces for a new generation of vascular devices. Interactive implantable or injectable microdevices aimed at providing specific information upon demand from an external source will revolutionize disease prevention, as emphasis shifts toward monitoring cardiovascular risk exposure. There is no doubt that during the next 10 years, we will witness impressive technological progress in the field of cardiovascular implantable devices.
1994年,首个球囊可扩张冠状动脉支架被批准“用于预防再狭窄”,同年《血管内治疗杂志》创刊。自那时起,支架的发展与血管内介入这一新兴专业的发展齐头并进。创新者们不断推动探索冠状动脉以外的各种新型支架应用。颈动脉支架置入术、经颈静脉肝内门体分流术和覆膜支架就是其中一些现已变得常见的新应用。为解决支架内再狭窄问题,人们测试了数十种支架设计和几种新材料,但药物洗脱支架(DES)已成为最具前景的一种,至少在冠状动脉领域是如此。然而,DES技术的益处对于更普遍形式的支架内再狭窄可能并不有效,比如在股腘段所遇到的情况。未来,旨在刺激而非抑制组织对植入物反应的技术可能会成为下一波发展浪潮的一部分,因为我们要应对表现为渗漏和移位的不良和/或缓慢的组织整合问题。例如,在股浅动脉中,可通过使用具有组织友好内表面的非常灵活的血管内装置来解决导致骨折和脱位的机械应力问题,该内表面可促进支架快速内皮化以对抗运动和微创伤的生物学效应。纳米技术、微电子学和先进材料技术的快速发展将使表面工程师能够为新一代血管装置设计分子特异性表面。旨在根据外部源的需求提供特定信息的交互式可植入或可注射微型装置将彻底改变疾病预防方式,因为重点已转向监测心血管风险暴露。毫无疑问,在未来10年里,我们将见证心血管植入式装置领域取得令人瞩目的技术进步。